Company: TYRA
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0000950170-25-046124
Chunk: 223

Company: Tyra Biosciences, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 7
Chunk 223
---
 additional product candidates and expand our pipeline, maintain, expand, protect and enforce our intellectual property portfolio, and hire additional personnel. 

Our future research and development expenses may vary significantly based on a wide variety of factors, such as: 

•the number and scope, rate of progress, expense and results of our discovery and preclinical development activities and clinical trials; 

•the number of trials required for approval; 

•the number of sites included in each of our trials; 

•the countries in which the trials are conducted; 

•the length of time required to enroll eligible patients; 

•the number of patients that participate in the trials; 

•the ability to identify appropriate patients eligible for our clinical trials; 

•the number of doses that patients receive; 

•the drop-out or discontinuation rates of patients; 

•potential additional safety monitoring requested by regulatory agencies; 

•the duration of patient participation in the trials and follow-up; 

•the phase of development of the product candidate; 

•the efficacy and safety profile of the product candidate; 

•the timing, receipt, and terms of any approvals from applicable regulatory authorities including the FDA and non-U.S. regulators; 

•maintaining a continued acceptable safety profile of our product candidates following approval, if any; 

•the cost and timing of manufacturing our product candidates; 

•significant and changing government regulation and regulatory guidance; 

•the ability to attract and retain personnel;

•the impact of any business interruptions to our operations or to those of the third parties with whom we work;

•geopolitical instability, such as the war and other conflicts in Ukraine and the Middle East;

106

•adverse effects on the financial markets, the global economy, the supply chain and our expenses due to pandemic or epidemic diseases, geopolitical instability, inflation, interest rates and other factors; and

•the extent to which we establish additional strategic collaborations or other arrangements. 

A change in the outcome of any of these variables with respect to the development of any of our product candidates could significantly change the costs and timing associated with the development of that product candidate. 

The process of conducting the necessary preclinical and clinical research to obtain regulatory approval is costly and time-consuming. The actual probability of success for our product candidates or any future candidates may be affected by a variety of factors. We may never succeed in achieving regulatory approval for any of our product candidates or any future candidates. 

General and Administrative Expenses 

General and administrative expenses consist primarily of personnel-related expenses, including employee salaries, bonuses